Analyst Ratings For Pieris Pharmaceuticals (NASDAQ:PIRS)
Today, HC Wainwright reiterated its Buy rating on Pieris Pharmaceuticals (NASDAQ:PIRS) with a price target of $12.00.
Some recent analyst ratings include
- 3/9/2018-HC Wainwright Reiterated Rating of Buy.
- 1/17/2018-William Blair initiated coverage with a Outperform rating.
- 5/30/2017-Rodman & Renshaw initiated coverage with a Buy rating.
- 9/28/2016-Roth Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For Pieris Pharmaceuticals (NASDAQ:PIRS)
Pieris Pharmaceuticals (NASDAQ:PIRS) has insider ownership of 4.05% and institutional ownership of 47.19%.
- On 2/13/2018 Orbimed Advisors Llc, Major Shareholder, sold 7,897 with an average share price of $8.98 per share and the total transaction amounting to $70,915.06.
- On 1/3/2018 Orbimed Advisors Llc, Major Shareholder, sold 1,709,620 with an average share price of $7.35 per share and the total transaction amounting to $12,565,707.00.
- On 12/18/2017 Orbimed Advisors Llc, Major Shareholder, sold 147,635 with an average share price of $5.70 per share and the total transaction amounting to $841,519.50.
- On 8/17/2017 Allan Reine, Insider, bought 65,000 with an average share price of $4.82 per share and the total transaction amounting to $313,300.00.
- On 8/17/2017 James A Geraghty, Director, bought 10,000 with an average share price of $4.82 per share and the total transaction amounting to $48,200.00.
- On 6/14/2016 Louis Matis, SVP, bought 10,000 with an average share price of $1.70 per share and the total transaction amounting to $17,000.00.
- On 6/13/2016 Darlene M Deptula-Hicks, CFO, bought 5,000 with an average share price of $1.66 per share and the total transaction amounting to $8,300.00.
Recent Trading Activity for Pieris Pharmaceuticals (NASDAQ:PIRS)
Shares of Pieris Pharmaceuticals closed the previous trading session at 7.11 down -0.29 3.95% with 6.630000114440918 shares trading hands.